Vascular endothelial growth factor: biology and therapeutic applications.

摘要: While the development of anti-angiogenic therapy, as it pertains to cancer treatment, may still be in its infancy relative well-established modalities such chemotherapy, radiation, and surgery, major strides made past several decades have allowed translation basic science discoveries this field into clinical reality. The discovery key molecular modulators angiogenesis, notably vascular endothelial growth factor (VEGF), has catalyzed numerous neutralizing therapeutic agents. validity VEGF inhibition a strategy been well supported randomized trials, U.S. Food Drug Administration approval antagonists bevacizumab, sunitinib malate, sorafenib, pegaptinib ranibizumab. Accordingly, review will (1) briefly biology (2) summarize recent progress targeting pathway therapy for angiogenic diseases age-related macular degeneration.